Scisparc Stock Price, News & Analysis

SciSparc Ltd. (Nasdaq: SPRC) announced promising pre-clinical results in collaboration with Clearmind Medicine Inc. for treating obesity and metabolic disorders using a novel psychedelic molecule, MEAI. The study showed that MEAI led to a 20% weight loss in rodents while preserving lean mass. Additionally, this treatment improved insulin levels and glucose tolerance. SciSparc aims to penetrate the obesity treatment market projected to grow from $2.4 billion in 2022 to $54 billion by 2030. This collaboration highlights the potential for developing a significant drug candidate in an underserved market.

SciSparc Ltd. (Nasdaq: SPRC) announced a non-binding letter of intent to sell a 50% stake in its subsidiary, SciSparc Nutraceuticals Inc., which owns the Wellution^TM brand, to Jeffs' Brands Ltd. for $3 million. The transaction is contingent on a definitive agreement. The company also plans to establish a joint venture with Jeffs' Brands for a new line of food supplements. Wellution^TM is a leading seller on Amazon with over 40,000 product reviews, primarily rated highly.

SciSparc Ltd. (Nasdaq: SPRC) announced positive findings from its non-clinical study of SCI-210 for treating Status Epilepticus (SE) at Chaim Sheba Medical Center, Israel. The study revealed that SCI-210, combining Palmitoylethanolamide (PEA) and Cannabidiol (CBD), showed significantly improved neuronal protection and no mortality in tested models compared to control groups. The results suggest SCI-210 may be more effective than CBD alone, with lower concentration requirements. The press release emphasizes the potential benefits of SCI-210 for SE patients, highlighting a gap in effective treatments.

SciSparc Ltd. (Nasdaq: SPRC) announced on Nov. 29, 2022, that it has regained compliance with Nasdaq's Listing Rule 5550(a)(2), which mandates a minimum bid price of $1.00 per share. This decision follows a period where the company's ordinary shares maintained a closing bid price of at least $1.00 for ten consecutive business days. With this compliance achieved, the previous bid price deficiency matter is now resolved.

On November 15, 2022, SciSparc Ltd. (Nasdaq: SPRC) announced its intention to form a joint venture with Jeffs' Brands Ltd. (Nasdaq: JFBR) to develop a new line of nutritional and dietary supplements. Both companies will hold a 50% stake in the joint venture, which is subject to definitive documentation. SciSparc will handle product development, leveraging Jeffs' Brands' e-commerce expertise for marketing. This collaboration aims to create products based on market demand analysis for high profitability, potentially enhancing both companies' market positions.

SciSparc Ltd. (Nasdaq: SPRC) has received a new patent (U.S. Patent No. 11,491,172) for compositions and methods enhancing antimicrobials. This marks the seventh patent granted in the U.S. and strengthens the company’s intellectual property portfolio, comprising nine patent families and two trademarks. SciSparc is a clinical-stage pharmaceutical firm focused on cannabinoid-based therapies, including treatments for Tourette Syndrome, Alzheimer's disease, pain, and autism spectrum disorder.

SciSparc Ltd. (Nasdaq: SPRC) announced positive interim results from its Phase IIa trial of SCI-110 for patients with Alzheimer’s Disease and agitation. The trial demonstrated that SCI-110 was safe at all tested doses, without serious adverse effects. Notably, 75% of participants did not require additional medications for agitation, and 75% experienced increased appetite. The open-label study included 20 patients, with interim results based on the first eight. SCI-110 aims to address the unmet need for safe treatment options in this patient population.

SciSparc Ltd. (Nasdaq: SPRC) recently announced a strategic agreement through its subsidiary, SciSparc Nutraceuticals, to enhance logistics operations in New Jersey. This new partnership aims to optimize handling and shipment processes to facilitate direct sales and lower costs for the Wellution™ brand. The logistics facilities, located near major transportation hubs, will support the brand's expansion from Amazon to other e-commerce platforms. CEO Oz Adler emphasized that improved operational efficiency is essential for high-margin sales as they prepare to launch direct sales operations.

SciSparc Ltd. (Nasdaq: SPRC) announced the launch of its new Wellution™ brand keto gummies on Amazon, generating over $100,000 in revenue within the first 30 days. The product achieved approximately 117% ROI after accounting for costs. CEO Oz Adler highlighted plans for further expansion, including new product launches and cost reductions. The company is focused on cannabinoid pharmaceuticals and has ongoing drug development programs targeting disorders such as Tourette Syndrome and Alzheimer's.